Skip to main content
SpringerLink
Log in

Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Vasopressin (AVP) plays a role in regulating anxiety, which is thought to be partially mediated through the V1a receptor. Recently, JNJ-17308616 was identified as a V1a antagonist.

Objectives

The purpose of this work was to assess V1a receptor affinity and selectivity of JNJ-17308616 and in vivo efficacy in animal models of anxiety-like behavior.

Materials and methods

The affinity of JNJ-17308616 for the human and rat V1a, V1b, V2, and oxytocin receptors was determined. Central administration of AVP induces a scratching response mediated through the V1a receptor. Inhibition of scratching was used as a behavioral measure of in vivo potency. JNJ-17308616 was tested in five models of anxiety: rat elevated plus-maze (EPM), rat-elevated zero-maze (EZM), rat-conditioned lick suppression (CLS), rat pup separation-induced ultrasonic vocalizations (USV), and mouse marble burying (MMB).

Results

High affinity for the human V1a receptor (K i 5.0 nM) was confirmed. However, the rat V1a receptor affinity was more modest (K i 216 nM), and the compound was not selective over the rat V2 receptor (K i 276 nM). At 100 mg/kg, JNJ-17308616 significantly reduced anxiety-like behavior in EPM, USV, and MMB; at 30 mg/kg, it was effective in EZM and CLS. JNJ-17308616 neither impaired social recognition nor reduced locomotor activity.

Conclusions

These results demonstrate the potential for V1a receptor antagonists as novel anxiolytics. Tool compounds that have greater V1a receptor selectivity than JNJ-17308616 are necessary to make precise conclusions about the role of the V1a receptor in affective disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  • Bielsky IF, Hu SB, Szegda KL, Westphal H, Young LJ (2004) Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology 29:483–493

    Article  PubMed  CAS  Google Scholar 

  • Egashira N, Tanoue A, Higashihara F, Mishima K, Fukue Y, Takano Y, Tsujimoto G, Iwasaki K, Fujiwara M (2004) V1a receptor knockout mice exhibit impairment of spatial memory in an eight-arm radial maze. Neurosci Lett 356:195–198

    Article  PubMed  CAS  Google Scholar 

  • Egashira N, Tanoue A, Matsuda T, Koushi E, Harada S, Tanako Y, Tsujimoto G, Mishima K, Iwasaki K, Fujiwara M (2007) Impaired social interaction and reduced anxiety-like behavior in vasopressin V1a receptor knockout mice. Behav Brain Res 178:123–127

    Article  PubMed  CAS  Google Scholar 

  • Everts HG, Koolhaas JM (1999) Differential modulation of lateral septal vasopressin receptor blockade in spatial learning, social recognition, and anxiety-related behaviors in rats. Behav Brain Res 99:7–16

    Article  PubMed  CAS  Google Scholar 

  • Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002) Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci U S A 99:6370–6375

    Article  PubMed  CAS  Google Scholar 

  • Griebel G, Simiand J, Stemmelin J, Gal CS, Steinberg R (2003) The vasopressin V1b receptor as a therapeutic target in stress-related disorders. Curr Drug Targets CNS Neurol Disord 2:191–200

    Article  PubMed  CAS  Google Scholar 

  • Gunnet JW, Look R, Vaidya AH, Xiang M, Chen RH, Combs DW, Demarest KT. The characterization of JNJ-17308616: a potent and selective vasopressin-1A (V1a) receptor antagonist. Program No 115.1. 2004 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2004. Online

  • Hodgson RA, Guthrie DG, Pond AJ, Morgan C, Lu X, Mullins D, Miller M, Stamford A, Guzzi M, Parker EM, Varty GB. Characterization of a novel nonselective V1a/b antagonist (SCH 756491) in animal models of anxiety-like behavior. Program No. 828.6 2006 Neuroscience Meeting Planner. Atlanta, GA: Society for Neuroscience, 2006. Online

  • Hodgson RA, Higgins GA, Guthrie DH, Lu SX, Pond AJ, Mullins DE, Guzzi MF, Parker EM, Varty GB (2007) Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression. Pharmacol Biochem Behav 86:431–440

    Article  PubMed  CAS  Google Scholar 

  • Iijima M, Chaki S (2007) An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model. Prog Neuropsychopharmacol Biol Psychiatry 31:622–627

    Article  PubMed  CAS  Google Scholar 

  • Kilts CD, Commissaris R, Rech RH (1981) Comparison of anti-conflict drug effects in three experimental animal models of anxiety. Psychopharmacology (Berl) 74:290–296

    Article  CAS  Google Scholar 

  • Liebsch G, Wotjak CT, Landgraf R, Engelmann M (1996) Septal vasopressin modulates anxiety-related behaviour in rats. Neurosci Lett 217:101–104

    Article  PubMed  CAS  Google Scholar 

  • Lu SX, Carey GJ, Varty GB Nociceptin produces anxiolytic-like effects in a rat conditioned lick suppression model. Program No. 683.1. Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2002. Online

  • Lumley LA, Robison CL, Chen WK, Mark B, Meyerhoff JL (2001) Vasopressin into the preoptic area increases grooming behavior in mice. Physiol Behav 73:451–455

    Article  PubMed  CAS  Google Scholar 

  • Meisenberg G (1988) Vasopressin-induced grooming and scratching behavior in mice. Ann N Y Acad Sci 525:257–269

    Article  PubMed  CAS  Google Scholar 

  • Murgatroyd C, Wigger A, Frank E, Singewald N, Bunck M, Holsboer F, Landgraf R, Spengler D (2004) Impaired repression at a vasopressin promoter polymorphism underlies over expression of vasopressin in a rat model of trait anxiety. J Neurosci 24:7762–7770

    Article  PubMed  CAS  Google Scholar 

  • Njung’e K, Handley SL (1991) Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 38:63–67

    Article  PubMed  CAS  Google Scholar 

  • Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005) An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders. CNS Drug Rev 11:53–68

    PubMed  CAS  Google Scholar 

  • Vaidya AH, Rosenthal D, Milewski M, Dubinsky B, Demarest KT, Chen RH, Combs DW, Reitz AB, Gunnet JW, Plata-Salaman CR. JNJ-17308616: A vasopressin-1A (V1A) receptor antagonist for the treatment of anxiety. Program No 115.2. Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2004. Online

  • Wersinger SR, Caldwell HK, Martinez L, Gold P, Hu SB, Young WS 3rd (2007) Vasopressin 1a receptor knockout mice have a subtle olfactory deficit but normal aggression. Genes Brain Behav 6:540–551

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurobiology, K-15-2600, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ, 07033, USA

    C. J. Bleickardt, D. E. Mullins, B. J. Werner, A. J. Pond, M. F. Guzzi, G. B. Varty & R. A. Hodgson

  2. Neurobiology Section, Department of Pharmacology, Schering-Plough Corporation, Newhouse, Motherwell, ML1 5SH, UK

    C. P. MacSweeney & F. D. C. Martin

Authors
  1. C. J. Bleickardt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. E. Mullins
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. P. MacSweeney
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. J. Werner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. J. Pond
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. F. Guzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F. D. C. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. B. Varty
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R. A. Hodgson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. A. Hodgson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bleickardt, C.J., Mullins, D.E., MacSweeney, C.P. et al. Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior. Psychopharmacology 202, 711–718 (2009). https://doi.org/10.1007/s00213-008-1354-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-008-1354-x

Keywords

Search

Navigation